IP Library › Patent Application 11198040
Patent Application
App. No. 11/198,040

Methods of use fluoroquinolone compounds against maxillary sinus pathogenic bacteria

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/198,040
Abstract

This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against maxillary sinus pathogenic pathogenic bacteria.

Claims (19)

1 - 11 . (canceled)

12 . A method of treating sinusitis, comprising administering to a sinusitis patient a composition comprising an antibacterially effective amount of gemifloxacin, gemifloxacin mesylate, or gemifloxacin mesylate sesquihydrate.

13 . The method of claim 12 , wherein the composition comprises an antibacterially effective amount of gemifloxacin mesylate.

14 . The method of claim 12 , wherein the composition comprises an antibacterially effective amount of gemifloxacin mesylate sesquihydrate.

15 . The method of claim 12 , wherein the sinusitis is maxillary sinusitis.

16 . The method of claim 15 , wherein the sinusitis is acute maxillary sinusitis.

17 . The method of claim 15 , wherein the sinusitis is chronic maxillary sinusitis.

18 . The method of claim 12 , wherein the sinusitis is caused by a pathogenic bacterium resistant to penicillin.

19 . The method of claim 12 , wherein the sinusitis is caused by a pathogenic bacterium resistant to ciprofloxacin.

20 . A method of treating acute maxillary sinusitis, comprising administering to an acute maxillary sinusitis patient a composition comprising an antibacterially effective amount of gemifloxacin, gemifloxacin mesylate, or gemifloxacin mesylate sesquihydrate.

21 . The method of claim 20 , wherein the composition comprises an antibacterially effective amount of gemifloxacin mesylate.

22 . The method of claim 20 , wherein the composition comprises an antibacterially effective amount of gemifloxacin mesylate sesquihydrate.

23 . The method of claim 20 , wherein the acute maxillary sinusitis is caused by a pathogenic bacterium resistant to penicillin.

24 . The method of claim 20 , wherein the acute maxillary sinusitis is caused by a pathogenic bacterium resistant to ciprofloxacin.

25 . A method of treating chronic maxillary sinusitis, comprising administering to a chronic maxillary sinusitis patient a composition comprising an antibacterially effective amount of gemifloxacin, gemifloxacin mesylate, or gemifloxacin mesylate sesquihydrate.

26 . The method of claim 25 , wherein the composition comprises an antibacterially effective amount of gemifloxacin mesylate.

27 . The method of claim 25 , wherein the composition comprises an antibacterially effective amount of gemifloxacin mesylate sesquihydrate.

28 . The method of claim 25 , wherein the chronic maxillary sinusitis is caused by a pathogenic bacterium resistant to penicillin.

29 . The method of claim 25 , wherein the chronic maxillary sinusitis is caused by a pathogenic bacterium resistant to ciprofloxacin.

Assignments (1)
CHANGE OF NAME Recorded Jun 18, 2026
From: TOPGOLF CALLAWAY BRANDS CORP.
To: CALLAWAY GOLF COMPANY
Reel/Frame 075933/0328 →